Funda Meric-Bernstam, MD

This episode highlights Dr Meric-Bernstam's evolution from a science-focused student into a leader in precision oncology and early-phase drug development.

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.

Funda Meric-Bernstam, MD, discusses a first-in-human phase 1/2 study of CBX-12 in patients with advanced or metastatic solid tumors.

Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of trastuzumab deruxtecan in difficult-to-treat HER2-positive solid tumors.

Funda Meric-Bernstam, MD, discusses the safety and efficacy of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumors.

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics, medical director of the Institute for Personalized Cancer Therapy, and a professor in the Divisions of Cancer Medicine and Surgery at The University of Texas MD Anderson Cancer Center, discusses the activity of the combination of telaglenastat (CB-839) and cabozantinib (Cabometyx) in heavily pretreated patients with metastatic renal cell carcinoma (mRCC).

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discussed preliminary data with a novel combination in the treatment of patients with renal cell carcinoma.

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.